Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Holdings Reduced by HighPoint Advisor Group LLC

HighPoint Advisor Group LLC lessened its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 14.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,797 shares of the biopharmaceutical company’s stock after selling 296 shares during the period. HighPoint Advisor Group LLC’s holdings in Regeneron Pharmaceuticals were worth $1,199,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in REGN. Norges Bank acquired a new position in Regeneron Pharmaceuticals during the 4th quarter worth $802,036,000. Amundi grew its position in Regeneron Pharmaceuticals by 45.8% in the 4th quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company’s stock valued at $1,138,074,000 after buying an additional 487,489 shares in the last quarter. Loomis Sayles & Co. L P grew its position in Regeneron Pharmaceuticals by 33.4% in the 4th quarter. Loomis Sayles & Co. L P now owns 1,575,349 shares of the biopharmaceutical company’s stock valued at $1,122,168,000 after buying an additional 393,997 shares in the last quarter. Proficio Capital Partners LLC increased its stake in Regeneron Pharmaceuticals by 92,865.3% during the 4th quarter. Proficio Capital Partners LLC now owns 219,398 shares of the biopharmaceutical company’s stock valued at $156,284,000 after buying an additional 219,162 shares during the period. Finally, Franklin Resources Inc. raised its position in shares of Regeneron Pharmaceuticals by 7.9% during the 4th quarter. Franklin Resources Inc. now owns 2,045,210 shares of the biopharmaceutical company’s stock worth $1,456,864,000 after buying an additional 149,124 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Trading Down 2.7 %

NASDAQ:REGN opened at $617.00 on Wednesday. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The company’s 50 day moving average is $681.52 and its 200-day moving average is $788.06. The firm has a market cap of $67.45 billion, a price-to-earnings ratio of 16.12, a P/E/G ratio of 2.34 and a beta of 0.27. Regeneron Pharmaceuticals, Inc. has a 12 month low of $612.78 and a 12 month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. During the same period in the prior year, the business earned $11.86 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up 10.3% compared to the same quarter last year. Equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were paid a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.57%. The ex-dividend date of this dividend was Thursday, February 20th. Regeneron Pharmaceuticals’s payout ratio is presently 2.30%.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on REGN shares. TD Cowen lowered their price target on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a research report on Tuesday, February 4th. UBS Group lowered Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $1,130.00 to $738.00 in a report on Thursday, January 16th. Truist Financial cut their price target on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a report on Wednesday, January 8th. Wells Fargo & Company lowered their price objective on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a research note on Friday, January 10th. Finally, Piper Sandler cut their target price on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating for the company in a research note on Monday, January 27th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $966.88.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.